Association of Angiotensin II Type 1 Receptor A1166C Gene Polymorphisms with Coronary Artery Disease in Thrace Region of Turkey
1Department of Cardiology, Trakya University Faculty of Medicine, Edirne, Turkey
2Trakya University Health Services Vocational College, Edirne, Turkey
3Department of Cardiology, Hisar Hospital Intercontinental, İstanbul, Turkey
4Department of Cardiology, Özel Güney Adana Hospital, Adana, Turkey
J Clin Pract Res 2021; 43(4): 337-342 DOI: 10.14744/etd.2020.90248
Full Text PDF

Abstract

Objective: Although the risk factors for coronary artery disease (CAD) are well established, a significant gap still exists in understanding the pathology of atherosclerotic heart disease evolving without conventional risk factors. Therefore, genetic factors are considered to play a significant role in this setting. The present study aimed to assess the relationship between angiotensin 2 type 1 receptor (AT1R) A1166C gene polymorphism and CAD.
Materials and Methods: Patients with documented CAD (n=121) were compared with controls with normal coronary arteries (n=121). CAD was diagnosed using a coronary angiography. The median age of participants was 59±12 years with an equal sex distribution. A comparison between the two groups with regard to the AT1R A1166C gene polymorphism was made through the amplification of DNA using polymerase chain reaction.
Results: This study demonstrated that adenine-adenine and cytosine-cytosine (CC) genotypes were more frequent, yet adenine-cytosine genotype was less frequent among patients with CAD compared with controls [p=0.003), 95% confidence interval (CI)]. The AT1R A1166C gene polymorphism along with the CC genotype and C allele was found to be associated with CAD. Further, gender, hypertension, family history, age, and low levels of serum high-density lipoprotein also had a significant relationship with AT1R A1166C gene polymorphism.
Conclusion: The present study suggested AT1R A1166C gene polymorphism, CC genotype, and C allele as potential risk factors for atherosclerotic CAD. Patients harboring these genetic variants should be under close supervision for the development of CAD.